Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC
Status:
Recruiting
Trial end date:
2033-12-13
Target enrollment:
Participant gender:
Summary
This is a phase 1 single center clinical trial for patients with end stage Metastatic
Castration Resistant Prostate Cancer who have progressed through standard of care treatment
options and are on zoledronate for bone metastases. This clinical trial includes a
dose-escalation phase and dose-expansion phase to assess the safety and preliminary efficacy
of treatment with autologous T cells genetically modified to express Prostate stem cell
antigen.
Phase:
Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute